Maintenance Drugs
1. VP-16
- Schaut , Nikki
2. Vioxx
- Orgel , Greg
3. Gleevec
- Schaut , Nikki - tumor started growing, stopped drug
4. Celebrex
- Payne , Steve
5. Irinotecan and Temodar
- Robertson, Nathan - stopped at 8 months, relapsed within 2 months
6. Sutent
Alternative and Complementary
1. Braswell, Chris
2. Orantes, Meliza
Clinical Studies
http://www3.interscience.wiley.com/cgi-bin/abstract/112151892/ABSTRACT?CRETRY=1&SRETRY=0
Response to vinorelbine and low-dose cyclophosphamide chemotherapy in two patients with desmoplastic small round cell tumor Andrea Ferrari, MD 1 *, Federica Grosso, MD 2, Silvia Stacchiotti, MD 2, Cristina Meazza, MD 1, Elena Zaffignani, MD 1, Alfonso Marchianò, MD 3, Michela Casanova, MD 1 1Pediatric Oncology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy 2Adult Sarcoma Medical Oncology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy 3Radiology Department, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy
email: Andrea Ferrari (andrea.ferrari@istitutotumori.mi.it)
- Correspondence to Andrea Ferrari, Pediatric Oncology Unit, Istituto Nazionale Tumori, Via G. Venezian, 1-20133 Milano MI, Italy.
Keywords desmoplastic small round cell tumor • low-dose cyclophosphamide • metronomic therapy • vinorelbine
Abstract
We report two cases of abdominal desmoplastic small round cell tumor (DSRCT) that showed a clinical response to the vinorelbine/low-dose cyclophosphamide combination that has been claimed to be effective for rhabdomyosarcoma. This observation may prompt further investigation into the activity of such a regimen in DSRCT patients with recurrent or refractory disease, with a view to a possible future role as maintenance therapy in controlling minimal residual disease in patients who achieve complete remission with intensive induction multimodality therapy. Pediatr Blood Cancer © 2005 Wiley-Liss, Inc.
DSRCT References
[BACK]